



AKADÉMIAI KIADÓ

Acta Microbiologica et
Immunologica Hungarica


67 (2020) 4, 228-233

DOI:
10.1556/030.2020.01273
© 2020 The Author(s)

RESEARCH ARTICLE



Prevalence and molecular epidemiology of ceftaroline non-susceptible methicillin-resistant *Staphylococcus aureus* isolates, first clinical report from Iran

AMIN KHOSHBAYAN¹, AREF SHARIATI¹,
EHSANOLLAH GHAZNAVI-RAD², ALEX VAN BELKUM³ and
DAVOOD DARBAN-SAROKHALIL^{1*} 

¹ Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

² Department of Medical Laboratory Sciences, Arak School of Paramedicine, Arak University of Medical Sciences, Arak, Iran

³ Open Innovation & Partnerships, Route de Port Michaud, 38390, La Balme Les Grottes, France

Received: August 11, 2020 • Accepted: September 21, 2020

Published online: December 1, 2020

ABSTRACT

Background: Methicillin-resistant *Staphylococcus aureus* (MRSA) is one of the major pathogens in Iran with a high prevalence and a high level of antibiotic resistance. Ceftaroline is a fifth generation cephalosporin binding and inhibiting penicillin binding protein (PBP2a). **Methods:** In the present study, 228 clinical MRSA isolates were collected from four cities of Iran and their susceptibility to ceftaroline was evaluated by E-test and the disk diffusion method. **Results:** Our results showed a high susceptibility rate (97.3%) to ceftaroline in MRSA strains from Iran. Six isolates were found to be ceftaroline non-susceptible (CPT-NS) with Minimum inhibitory concentration (MIC) ≥ 2 $\mu\text{g/mL}$. All CPT-NS isolates were isolated from blood and tracheal aspirate and belonged to SCCmec type III as well as agr type I and were all susceptible to vancomycin. Out of six isolates, three, two and one belonged to spa type t030, t4864, and t969, respectively. Vancomycin, quinupristin/dalfopristin, linezolid, chloramphenicol, and tigecycline were the most active agents against CPT-NS isolates. **Conclusion:** Due to the broad-spectrum activity and low toxicity of ceftaroline as well as the increased rate of vancomycin resistance among MRSA strains in recent years, ceftaroline can be considered as a novel approach to treat MRSA-induced infections.

KEYWORDS

ceftaroline, Fifth-generation cephalosporin, MRSA, *Staphylococcus aureus*, Iran

INTRODUCTION

Methicillin-resistant *Staphylococcus aureus* (MRSA) is one of the most important bacterial pathogens worldwide, causing a number of community-acquired and health care-associated infections, including septicemia, skin and soft tissue infections, osteomyelitis, and endocarditis [1]. The mean prevalence of MRSA in Iran is between 57.2 and 93.3 percent [2]. Antibiotic misuse has led to high resistance levels in MRSA strains leading to an increased mortality rate, high costs of care and treatment, and longer hospitalization periods [3]. The mechanism of resistance in MRSA is attributed to the presence of the *mecA* gene and the subsequent expression of penicillin binding protein 2a (PBP2a) which confers low affinity to common β -lactam antibiotics and hence, mediates resistance. Owing to high resistance rates to different antibiotics, treatment of MRSA infections has become challenging, necessitating the development of novel therapeutics [4]. Ceftaroline is a member of the fifth generation

*Corresponding author.
E-mail: darban.d@iums.ac.ir
Tel.: +98 2186703183;
fax: +98 2188058649

cephalosporins approved by the US Food and Drug Administration (FDA) for the treatment of adults with community-acquired bacterial pneumonia (CABP) as well as acute bacterial skin and skin structure infections (ABSSSI). There are also reports on the efficacy of this antibiotic for the treatment of other infections, such as osteomyelitis and epidural abscesses [5–7]. Furthermore, previous studies have shown the efficiency of this antibiotic against methicillin-susceptible *S. aureus* (MSSA), MRSA, and *Streptococcus pneumoniae* [8, 9]. This antibiotic is probably also efficient against other pathogens including *Streptococcus pyogenes*, *Haemophilus influenzae*, *Moraxella catarrhalis* and non-extended-spectrum β -lactamase-producing *Enterobacteriales*. Ceftaroline is notably the first cephalosporin with a unique feature of high affinity to penicillin binding protein 2a (PBP2a) with 800- and 1,400-fold lower half-maximal inhibitory concentration for PBP2a compared to oxacillin and ceftriaxone, respectively, making it a suitable choice for the treatment of MRSA infections [10–13]. Therefore, due to the efficiency of ceftaroline in previous studies, its fewer side effects, and the increased prevalence of vancomycin-resistant *S. aureus* (VRSA) in recent years [14], the aim of this study was to determine the frequency of ceftaroline-resistance in MRSA strains collected from different cities of Iran.

MATERIALS AND METHODS

Bacterial isolates

A total of 228 MRSA isolates were used in this study isolated from blood (37.2%), tracheal aspirate (21.8%), wound (18.2%), nasal swabs (6.9%), hospital surfaces (6.2%), abscess (4.3%) skin lesion (1.7%), catheter (1.4%), and bone aspiration (1.3%) were collected from hospitals in four cities in Iran (including Tehran, Karaj, Yasuj, and Arak) between 2015 and 2018. The isolates were identified at the species level by biochemical tests and Polymerase chain reaction (PCR) amplification of the *S. aureus*-specific *nucA* gene was performed as the confirmatory test [2, 3, 15, 16].

Antimicrobial susceptibility testing

The Liofilchem E-test strips (Roseto degli Abruzzi, Italy) as well as the Mast (Liverpool, UK) and BD (New Jersey, USA) antibiotic susceptibility discs were used for the determination of susceptibility profiles. Susceptibility to ceftaroline was tested by a ceftaroline disc (30 μ g) using the disk diffusion method in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines [15]. Susceptibility to ceftaroline was confirmed by gradient diffusion test (E-test) and the results were interpreted according to the CLSI and European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines [10, 17, 18]. Additional antibiotic susceptibility testing for ceftaroline non-susceptible (CPT-NS) strains was performed for the following antibiotics: nitrofurantoin (300 μ g), gentamicin (10 μ g), rifampicin (5 μ g), norfloxacin (10 μ g), tigecycline (15 μ g),

trimethoprim/sulfamethoxazole (25 μ g), chloramphenicol (30 μ g), cefixime (5 μ g), erythromycin (15 μ g), clindamycin (2 μ g), tetracycline (30 μ g), penicillin G (10 U), linezolid (30 μ g), cefepime (30 μ g), quinupristin/dalfopristin (15 μ g) ciprofloxacin (5 μ g), and imipenem (10 μ g) [19]. E-test gradient diffusion test was also performed for the determination of vancomycin resistance.

DNA extraction and molecular typing of MRSA strains

DNA extraction was performed by the boiling method using TE buffer (10 mM Tris, 1 mM EDTA [pH 8.0]) as previously described [20]. Identification of MRSA strains was performed by the detection of *mecA* using PCR.

spa typing

The *spa* gene was amplified using the method described by Harmsen et al. [21]. Amplicons were sent to Bioneer Co. (Seoul, South Korea) for DNA sequencing. Data were analyzed using the Ridom SpaServer database to determine the *Spa* type of each isolate (<http://www.spaserver.ridom.de>) [15, 16].

SCCmec typing

To determine the SCCmec types, a multiplex-PCR with four pairs of primers was performed according to the method described by Boye et al. [22, 23]. Each reaction contained 0.5 μ M of each primer and the final volume was 25 μ L. Finally, the PCR products were visualized by electrophoresis on 1% agarose gels containing safe stain (Kawsar Biotech Company, Iran) [15].

agr typing

To determine the *agr* types, PCR was performed as described by Shopsis et al. [24]. In brief, *agr* types (I–IV) were determined by multiplex PCR using the *agr*-specific primers. Each *agr* type was analyzed in each strain after visualization on 1% agarose gels containing safe stain [15].

RESULTS

Two hundred out of 228 strains [Tehran (95%), Yasuj (94%), Karaj (75%) and Arak (77%)] were ceftaroline susceptible upon disk diffusion. The Ceftaroline E-test strip was used to determine the MIC values on 28 strains were non-susceptible upon disk diffusion and according to the results, six isolates showed an MIC of 2 μ g/mL, including five isolates from Arak and one from Tehran (Fig. 1). These six isolates showed additional resistance to penicillin G, norfloxacin, gentamicin, erythromycin, cefepime, cefixime, ciprofloxacin, tetracycline, and imipenem and high resistance to clindamycin (83.33, $n = 5$) and rifampicin (83.33, $n = 5$) (Table 1). On the other hand, all CPT-NS isolates were susceptible to vancomycin, quinupristin/dalfopristin, linezolid, chloramphenicol, and tigecycline. The most frequent *spa* type was t030 (50%, $n = 3$), followed by t4864 (33.3%, n




Fig. 1. Results of Ceftaroline susceptibility testing by gradient diffusion test among MRSA isolates

Table 1. Antibiotic susceptibility pattern of the ceftaroline-nonsusceptible MRSA isolates by disk diffusion method

Antibiotics	Isolates N		
	Susceptible	Intermediate	Resistant
Cefepime	0 (0%)	0 (0%)	6 (100%)
Cefixime	0 (0%)	0 (0%)	6 (100%)
Chloramphenicol	6 (100%)	0 (0%)	0 (0%)
Ciprofloxacin	0 (0%)	0 (0%)	6 (100%)
Clindamycin	1 (16.7%)	0 (0%)	5 (83.3%)
Erythromycin	0 (0%)	0 (0%)	6 (100%)
Gentamicin	0 (0%)	0 (0%)	6 (100%)
Imipenem	0 (0%)	0 (0%)	6 (100%)
Linezolid	6 (100%)	0 (0%)	0 (0%)
Nitrofurantoin	1 (16.7%)	5 (83.3%)	0 (0%)
Norfloxacin	0 (0%)	0 (0%)	6 (100%)
Penicillin G	0 (0%)	0 (0%)	6 (100%)
Quinupristin/ Dalfopristin	6 (100%)	0 (0%)	0 (0%)
Rifampicin	1 (16.7%)	0 (0%)	5 (83.3%)
Tetracycline	0 (0%)	0 (0%)	6 (100%)
Tigecycline	6 (100%)	0 (0%)	0 (0%)
Trimethoprim/ Sulfamethoxazole	5 (83.3%)	0 (0%)	1 (16.7%)

= 2), and t969 (16.6%, $n = 1$). Moreover, all six isolates belonged to *agr* type I (100%, $n = 6$) and *SCCmec* type III (100%, $n = 6$) (Table 2).

DISCUSSION

S. aureus infections are one of the major problems around the world. In Iran, vancomycin has been frequently used to treat complex infections caused by *S. aureus*, but in recent years, resistance to this antibiotic has been reported, necessitating novel therapeutic antibiotics [25–27]. We

collected 228 MRSA from four different Iranian cities to evaluate the performance of ceftaroline against this pathogen. In a study by Dehkordi et al. on antibiotic resistance pattern of the MRSA isolated from hospital food, among 485 isolates, all of them were resistant to ceftaroline [28]. In addition, in another study on phenotypic and genotypic characterization of antibiotic resistance in the MRSA strains isolated from hospital cockroaches, all isolates recovered from external washing samples and gut content samples were resistance to ceftaroline [29]. Despite two previous studies from Iran in non-clinical samples, according to our research, this is the first report from Iran to evaluate the sensitivity of clinical MRSA isolates to ceftaroline. The results of the present study showed that 97.3% (222/228) of the MRSA isolates showed susceptibility to ceftaroline, while six isolates were non-susceptible. According to CLSI guideline, the susceptible dose dependent (SDD) range of ceftaroline is between 2 and 4 $\mu\text{g/mL}$, meanwhile EUCAST consider 2 $\mu\text{g/mL}$ as resistance [17, 18]. In this study, ceftaroline MIC 2 $\mu\text{g/mL}$ considered as non-susceptible. All six isolates were highly resistant to other beta-lactams, gentamicin, erythromycin, ciprofloxacin, norfloxacin, and tetracycline. on the other hand, they were completely inhibited by linezolid, vancomycin, quinupristin/dalfopristin, and tigecycline which is similar to other studies from Iran [2, 30]. In a study performed on 8037 *S. aureus*, four isolates were reported as CPT-NS strains which were susceptible to linezolid and vancomycin, and belonged to *SCCmec* types III [31]. In a study from Switzerland, 24% (23/96) of MRSA collected from deep infections, blood cultures, and superficial infections with $\text{MIC} \geq 2 \text{ mg/L}$ were reported as CPT-NS [32]. In the Atlas program, in which the ceftaroline susceptibility of *S. aureus* isolates from different countries was tested, 93.7% of the isolates were susceptible to this antibiotic, 5.9% were susceptible-dose dependent (SDD) and only 0.4% (263/61,045) were found to be resistant. Among

Table 2. Resistance patterns

Isolate	Source	Specimen	<i>spa</i>	SCC <i>mec</i>	<i>agr</i>	Vancomycin MIC	Resistance Pattern
B123	Tehran	Blood	t4864	III	I	1	NOR, IMI, T, GM, CIP, CFM, FEP, E, TS, PG
Ar33	Arak	Blood	t030	III	I	0.75	NOR, RIF, CD, IMI, T, GM, CIP, CFM, FEP, E, PG
Ar44	Arak	Blood	t4864	III	I	0.75	NOR, RIF, CD, IMI, T, GM, CIP, CFM, FEP, E, PG
Ar59	Arak	Tracheal aspirate	t030	III	I	1	NOR, RIF, CD, IMI, T, GM, CIP, CFM, FEP, E, PG
Ar61	Arak	Blood	t030	III	I	0.75	NOR, RIF, CD, IMI, T, GM, CIP, CFM, FEP, E, PG
Ar72	Arak	Tracheal aspirate	t969	III	I	0.75	NOR, RIF, CD, IMI, T, GM, CIP, CFM, FEP, E, PG

NOR: Norfloxacin. IMI: Imipenem. T: Tetracycline. GM: Gentamicin. CIP: Ciprofloxacin. CFM: Cefixime. FEP: Cefepime. E: Erythromycin. TS: Trimethoprim/Sulfamethoxazole. PG: Penicillin G. RIF: Rifampicin. CD: Clindamycin.

the resistant strains, 92% (242/263) were from Asia and similar to our results, all bacterial isolates were susceptible to vancomycin and linezolid and the highest resistance rate was reported to clindamycin, erythromycin, and gentamicin. Apparently, the rate of resistance to ceftaroline, gentamicin, clindamycin, and minocycline among MRSA isolates was much higher in the Asia-Pacific region compared to other parts of the world [33]. According to a study performed by Pfaller et al. including 1732 community-acquired MRSA isolates from the United States, only 3.1% were CPT-NS and all these isolates were susceptible to vancomycin, linezolid, and tigecycline [1]. Moreover, the results of another study showed that 100% non-duplicate MRSA isolated from different samples of hospitalized patients, were susceptible to ceftaroline, while 63% were resistant to gentamicin, erythromycin, clindamycin, and ciprofloxacin and 15% were resistant to vancomycin [34]. Finally, Sader et al. reported that all 523 studied *S. aureus* were susceptible to ceftaroline, and this antibiotic could be used as surgical prophylaxis that would cover all MRSA infections [35].

Our CPT-NS strains had *agr* types I and SCC*mec* types III which has been related to hospital-acquired infection and has been reported as the main SCC*mec* type in Iran with a prevalence between 45% and 76% [2]. Half of these non-susceptible isolates were obtained from Arak city and characterized with *spa* type t030 which is one of the most common *spa* types in Iran and seemingly most of them reported to be member of ST239-CC8. To date, this clone is spreading in several countries across Asia [2, 36]. Moreover, in study on susceptibility to ceftaroline and molecular epidemiology of MRSA isolates in China, results revealed that the 95.2% of CPT-NS isolates were belong to CC8. Additionally, the CPT-NS CC8 isolates were largely ST239-III-t030 and ST239-III-t037 [37]. The results of a systematic review which evaluated the clinical outcomes and side effects of ceftaroline showed that this antibiotic improves the treatment of severe MRSA infections [38]. In addition, drug toxicity was infrequent and was only observed in case of

long-term use, and evaluation of blood parameters is recommended [38]. Therefore, due to high efficacy and low toxicity of ceftaroline, recently increased vancomycin resistance, high cost of linezolid and unavailability of daptomycin in Iran, ceftaroline may be considered as a suitable alternative to treat MRSA-induced infections. However, given the varying degrees of resistance in different areas, it is suggested to perform more comprehensive studies to fully investigate the mechanism and frequency of ceftaroline nonsusceptibility in MRSA strains.

Funding: This research was supported by grant No: 98-1-4-14452 from Iran University of Medical Sciences.

Competing interests: AvB is a bioMerieux employee. bioMerieux is a company that design, develops and sells diagnostics in the field on infectious diseases. The company had no direct influence on the design and execution of the present study. Rest of the authors declare to have no competing interest.

Author contribution: AKH, ASH, and DDS conceived and designed the study. EGHR and DDS contributed in comprehensive research. AKH, ASH and DDS wrote the paper. DDS and AvB participated in manuscript editing.

Ethics approval and consent to participate: It was obtained from the ethics committee of Iran University of medical science. Reference number: IR.IUMS.FMD.REC.1398.032.

Consent for publication: Not applicable.

Availability of data and materials: All data were included.

ACKNOWLEDGEMENTS

Not applicable.



REFERENCES

- [1] Pfaller MA, Sader HS, Rhomberg PR, Flamm RK, Mendes RE. In vitro activity of tedizolid in comparison with other oral and intravenous agents against a collection of community-acquired methicillin-resistant *Staphylococcus aureus* (2014–2015) in the United States. *Microb Drug Resist* 2019; 25(6): 938–43.
- [2] Bayat B, Zade MH, Mansouri S, Kalantar E, Kabir K, Zahmatkesh E, et al. High frequency of methicillin-resistant *Staphylococcus aureus* (MRSA) with SCC mec type III and spa type t030 in Karaj's teaching hospitals, Iran. *ACTA Microbiol Imm H* 2017; 64(3): 331–41.
- [3] Bijari A, Zade MH, Hatami S, Kalantar E, Sepehr MN, Kabir K, et al. High frequency of methicillin-resistant *Staphylococcus aureus* in intensive care unit in Karaj, Iran. *Arch Clin Infect Dis* 2018; 13(5).
- [4] Chan LC, Basuino L, Diep B, Hamilton S, Chatterjee SS, Chambers HF. Ceftobiprole- and ceftaroline-resistant methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2015; 59(5): 2960–3.
- [5] Jacqueline C, Amador G, Caillon J, Le Mabecque V, Batard E, Miègeville A-F, et al. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant *Staphylococcus aureus* acute osteomyelitis. *J Antimicrob Chemother* 2010; 65(8): 1749–52.
- [6] Lalikian K, Parsiani R, Won R, Chang E, Turner RB. Ceftaroline for the treatment of osteomyelitis caused by methicillin-resistant *Staphylococcus aureus*: a case series. *J Chemother* 2018; 30(2): 124–8.
- [7] Lin JC, Aung G, Thomas A, Jahng M, Johns S, Fierer J. The use of ceftaroline fosamil in methicillin-resistant *Staphylococcus aureus* endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. *J Infect Chemother* 2013; 19(1): 42–9.
- [8] Karlowsky JA, Adam HJ, DeCorby MR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009. *Antimicrob Agents Chemother* 2011; 55(6): 2837–46.
- [9] Rolston KV, Jamal MA, Nesher L, Shelburne SA, Raad I, Prince RA. In vitro activity of ceftaroline and comparator agents against Gram-positive and Gram-negative clinical isolates from cancer patients. *Int J Antimicrob Agents* 2017; 49(4): 416–21.
- [10] Lee H, Yoon E-J, Kim D, Kim JW, Lee K-J, Kim HS, et al. Ceftaroline resistance by clone-specific polymorphism in penicillin-binding protein 2a of methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2018; 62(9): e00485–18.
- [11] Pani A, Colombo F, Agnelli F, Frantellizzi V, Baratta F, Pastori D, et al. Off-label use of ceftaroline fosamil: a systematic review. *Int J Antimicrob Agents* 2019; 54(5): 562–71.
- [12] Sanchez EH, Mendes RE, Sader HS, Allison GM. In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis. *J Antimicrob Chemother* 2016; 71(6): 1736–8.
- [13] Welte T, Kantecki M, Stone GG, Hammond J. Ceftaroline fosamil as a potential treatment option for *Staphylococcus aureus* community-acquired pneumonia in adults. *Int J Antimicrob Agents* 2019; 54(4): 410–22.
- [14] Shariati A, Dadashi M, Moghadam MT, van Belkum A, Yaslianifard S, Darban-Sarokhalil D. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate *Staphylococcus aureus* clinical isolates: a systematic review and meta-analysis. *Sci Rep* 2020; 10(1): 1–16.
- [15] Abbasian S, Farahani NN, Mir Z, Alinejad F, Haeili M, Dahmardehi M, et al. Genotypic characterization of *Staphylococcus aureus* isolated from a burn centre by using agr, spa and SCCmec typing methods. *New Microbes New Infect* 2018; 26: 15–9.
- [16] Darban-Sarokhalil D, Khoramrooz SS, Marashifard M, Hosseini SAAM, Parhizgari N, Yazdanpanah M, et al. Molecular characterization of *Staphylococcus aureus* isolates from southwest of Iran using spa and SCCmec typing methods. *Microb Pathog* 2016; 98: 88–92.
- [17] European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 9.0. Basel, Switzerland: EUCAST; 2019. Available from: <http://www.eucast.org>.
- [18] Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Wayne, PA: Clinical and Laboratory Standards Institute; 2019.
- [19] Tan SY, Tatsumura Y. Alexander Fleming (1881–1955): discoverer of penicillin. *Singap Med J* 2015; 56(7): 366.
- [20] Pourhajibagher M, Mokhtaran M, Esmaeili D, Bahador A. Antibiotic resistance patterns among *Acinetobacter baumannii* strains isolated from burned patients; 2016.
- [21] Harmsen D, Claus H, Witte W, Rothgänger J, Claus H, Turnwald D, et al. Typing of methicillin-resistant *Staphylococcus aureus* in a university hospital setting by using novel software for spa repeat determination and database management. *J Clin Microbiol* 2003; 41(12): 5442–8.
- [22] Boye K, Bartels MD, Andersen IS, Moeller JA, Westh H. A new multiplex PCR for easy screening of methicillin-resistant *Staphylococcus aureus* SCCmec types I–V. *Clin Microbiol Infect* 2007; 13(7): 725–7.
- [23] Turlej A, Hryniewicz W, Empel J. Staphylococcal cassette chromosome mec (Sccmec) classification and typing methods: an overview. *Pol J Microbiol* 2011; 60(2): 95–103.
- [24] Shopsis B, Mathema B, Alcibes P, Said-Salim B, Lina G, Matsuka A, et al. Prevalence of agr specificity groups among *Staphylococcus aureus* strains colonizing children and their guardians. *J Clin Microbiol* 2003; 41(1): 456–9.
- [25] Fasihi Y, Saffari F, Mansouri S, Kalantar-Neyestanaki D. The emergence of vancomycin-resistant *Staphylococcus aureus* in an intensive care unit in Kerman, Iran. *Wien Med Wochenschr* 2018; 168(3–4): 85–8.
- [26] Jahanshahi A, Zeighami H, Haghi F. Molecular characterization of methicillin and vancomycin resistant *Staphylococcus aureus* strains isolated from hospitalized patients. *Microb Drug Resist* 2018; 24(10): 1529–36.
- [27] Asadpour L, Ghazanfari N. Detection of vancomycin non-susceptible strains in clinical isolates of *Staphylococcus aureus* in northern Iran. *Int Microbiol* 2019: 1–7.
- [28] Dehkordi FS, Gandomi H, Basti AA, Misaghi A, Rahimi E. Phenotypic and genotypic characterization of antibiotic resistance of methicillin-resistant *Staphylococcus aureus* isolated from hospital food. *Antimicrob Resist Infect Control* 2017; 6(1): 104.
- [29] Abdolmaleki Z, Mashak Z, Dehkordi FS. Phenotypic and genotypic characterization of antibiotic resistance in the

- methicillin-resistant *Staphylococcus aureus* strains isolated from hospital cockroaches. *Antimicrob Resist Infect Control* 2019; 8(1): 1–14.
- [30] Abbasi-Montazeri E, Khosravi AD, Feizabadi MM, Goodarzi H, Khoramrooz SS, Mirzaii M, et al. The prevalence of methicillin resistant *Staphylococcus aureus* (MRSA) isolates with high-level mupirocin resistance from patients and personnel in a burn center. *Burns* 2013; 39(4): 650–4.
- [31] Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN. In vitro activity of ceftaroline against multidrug-resistant *Staphylococcus aureus* and *Streptococcus pneumoniae*: a review of published studies and the AWARE surveillance program (2008–2010). *Clin Infect Dis* 2012; 55(suppl. 3): S206–14.
- [32] Andrey D, Francois P, Manzano C, Bonetti E, Harbarth S, Schrenzel J, et al. Antimicrobial activity of ceftaroline against methicillin-resistant *Staphylococcus aureus* (MRSA) isolates collected in 2013–2014 at the Geneva University Hospitals. *Eur J Clin Microbiol Infect Dis* 2017; 36(2): 343–50.
- [33] Zhang Z, Chen M, Yu Y, Liu B, Liu Y. In vitro activity of ceftaroline and comparators against *Staphylococcus aureus* isolates: results from 6 years of the ATLAS program (2012 To 2017). *Infect Drug Res* 2019; 12: 3349.
- [34] ElFeky DS, Awad AR, Elshobaky MA, Elawady BA. Effect of ceftaroline, vancomycin, gentamicin, macrolides, and ciprofloxacin against methicillin-resistant *Staphylococcus aureus* isolates: an in vitro study. *Surgical Infect* 2020; 21(2): 150–7.
- [35] Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline tested against *Staphylococcus aureus* from surgical skin and skin structure infections in US medical centers. *Surgical Infect* 2016; 17(4): 443–7.
- [36] Asadollahi P, Farahani NN, Mirzaii M, Khoramrooz SS, van Belkum A, Asadollahi K, et al. Distribution of the most prevalent spa types among clinical isolates of methicillin-resistant and -susceptible *Staphylococcus aureus* around the world: a review. *Front Microbiol* 2018; 9(163).
- [37] Zhang H, Xiao M, Kong F, O'Sullivan MV, Mao L-L, Zhao H-R, et al. A multicentre study of methicillin-resistant *Staphylococcus aureus* in acute bacterial skin and skin-structure infections in China: susceptibility to ceftaroline and molecular epidemiology. *Int J Antimicrob Agents* 2015; 45(4): 347–50.
- [38] Cosimi RA, Beik N, Kubiak DW, Johnson JA, editors. Ceftaroline for severe methicillin-resistant *Staphylococcus aureus* infections: a systematic review. *Open forum infectious diseases*. Oxford University Press; 2017.